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http://www.hqlo.com/content/12/1/155RESEARCH Open AccessDevelopment of a tool to recognize small airways
dysfunction in asthma (SADT)
Lieke Schiphof-Godart1,2†, Erica van der Wiel2,3†, Nick HT ten Hacken2,3, Maarten van den Berge2,3,
Dirkje S Postma2,3† and Thys van der Molen1,2*†Abstract
Background: Small airways dysfunction (SAD) contributes to the clinical expression of asthma. The identification of
patients who suffer from SAD is important from a clinical perspective, as targeted therapy may improve patients’
well-being and treatment efficacy.
Aims: We aimed to realize the first step in the development of a simple small airways dysfunction tool (SADT) that
may help to identify asthma patients having SAD.
Methods: Asthma patients with and without SAD were interviewed. Patients were selected to participate in this
study based on FEF50% and R5-R20 values from spirometry and impulse oscillometry respectively.
Results: Ten in depth interviews and two focus groups revealed that patients with and without SAD perceived
differences in symptoms and signs, habits and health related issues. For example, patients with SAD reported to
wheeze easily, were unable to breathe in deeply, mentioned more symptoms related to bronchial
hyperresponsiveness, experienced more pronounced exercise-induced symptoms and more frequently had allergic
respiratory symptoms after exposure to cats and birds. Based on these differences, 63 items were retained to be
further explored for the SADT.
Conclusions: The first step of the development of the SADT tool shows that there are relevant differences in
signs and respiratory symptoms between asthma patients with and without SAD. The next step is to test and
validate all items in order to retain the most relevant items to create a short and simple tool, which should be
useful to identify asthma patients with SAD in clinical practice.
Keywords: Small airways dysfunction, Asthma, QuestionnaireIntroduction
Asthma is one of the most common chronic diseases in
people of all ages in developed countries [1]. Frequently
reported symptoms are breathlessness, chest tightness,
wheeze, cough, limitation of physical activity, and noctur-
nal awakening. Large airways obstruction due to inflam-
mation and remodeling was traditionally thought to be the
origin of these symptoms. However, there is growing con-
sensus that the small airways are also affected, and play a* Correspondence: t.van.der.molen@umcg.nl
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article, unless otherwise stated.role in the clinical expression of asthma [2,3]. A recent
systematic review showed that small airways dysfunction
(SAD) is associated with worse asthma control, a higher
number of exacerbations, the presence of nocturnal
asthma, more severe bronchial hyperresponsiveness (BHR)
and exercise-induced asthma [4]. Moreover, clinical studies
have shown that small particle treatment with inhaled
corticosteroids reduces the number of exacerbations and
improves asthma control [5-7]. Thus, it has become in-
creasingly important to identify those asthma patients in
whom SAD is present. Several tests are available to assess
SAD in patients with asthma, like the forced expiratory
flow rates at 50 or at 25 to 75% of the forced vital capacity
(FEF50% or FEF25–75%) which can easily be assessed
with spirometry [8-10]. This FEF is closely related to air
trapping on an expiratory CT-scan [11,12]. In addition,d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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measure the resistance of the small and large airways [10].
Another method that could help to assess the presence
of SAD in asthma patients is by identifying symptoms
associated with SAD. These could then be used in a
questionnaire to assess both the probability of SAD and
the burden of symptoms associated with SAD. So far, it has
not been studied whether small or large airways obstruc-
tion in asthma generates different symptoms. This may
well be the case, since small airways have a smaller
lumen size than large airways and lack cartilage. There-
fore, smooth muscle contraction may lead to a collapse
of the small airways, contributing to air trapping and
the perception of chest tightness [13]. Additionally, there
is a difference in vagal innervation between the large
airways and deeper lung structures, including the
small airways [14,15]. Finally, not all environmental
stimuli are able to reach the small airways. This de-
pends on the particle size, aerodynamic properties and
local airway flow characteristics. For instance, cat al-
lergen may reach the peripheral airways, whereas most
pollen will never do so because of their large particle
size [16,17].Figure 1 Flowchart of the study with the selection of the study populat
FEV1= Forced expiratory flow in one second, FVC= forced vital capacity, FEF50%
R5-R20: Difference between the resistance at 5 Hz and 20 Hz.Thus, this study aims to determine which self-reported
differences in symptoms might potentially differentiate
between asthma patients with SAD and without SAD. In
the future, these items might be used to create a tool to
recognize SAD in asthma in daily clinical practice, the
SADT.
Methods
Selection of study population
The participants were selected out of a database of patients
attending the Primary Care asthma/COPD service of “Certe
Laboratory” (The Netherlands) [18]. This database contains
3,721 patients with a doctor’s diagnosis of asthma. We
selected asthma patients aged between 18 and 75 years
with spirometry according to the American Thoracic
Society (ATS) criteria available (Figure 1). This group
(n= 1,578) was divided into three groups (tertiles) based
on their post-bronchodilator FEF50% percent predicted, in
order to select patient populations with and without prob-
able SAD. The 33% patients (n= 526) with the lowest
FEF50% represented the group of asthma patients with
probable SAD and the 33% patients (n= 526) with the
highest FEF50% the group (probably) without SAD. Since aion. ATS: American Thoracic Society, BHR: Bronchial hyperresponsiveness,
= forced expiratory flow at 50% of the FVC, LLN: lower limit of normal,
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values and the false interpretation of existing SAD, we de-
cided to exclude patients with an FVC<90% predicted,
leaving 398 patients in the group with SAD and 491 pa-
tients in the group without SAD. Characteristics of the
source population are shown in Table 1.
General practitioners were contacted and asked for per-
mission to contact their patients eligible for this study. Pa-
tient recruitment continued until saturation with respect
to content was reached. Finally, 120 patients from the
lowest tertile and 150 patients from the highest tertile
were invited to participate in this study and a total of
65 patients accepted to participate. They completed the
asthma control questionnaire (ACQ), the Clinical COPD
Questionnaire (CCQ) and the Bronchial Hyperresponsive-
ness Questionnaire (BHQ), and performed measurements
of spirometry, impulse oscillometry and a methacholine
provocation test (methods of the measurements are de-
scribed in the Additional file 1). Four patients were unable
to perform spirometry and were excluded. Patients with
BHR (n= 34), i.e. a provocative concentration causing a 20%
fall in FEV1 (PC20) methacholine bromide ≤39.3 mg/ml,
were included for further analysis.In-depth interviews and focus groups
First, explorative interviews were performed aiming to col-
lect topics for the focus group interviews. For these in-
depth interviews, 7 patients with and 3 without SAD were
selected, based on current FEF50% values lower or higher
than the lower limit of normal (LLN). One patient from
the highest tertile FEF50% had an FEF50% of 45% predicted
with current spirometry and switched to the group selec-
tion with SAD.
Patients were asked about their symptoms, age of asthma
onset, possibly related illnesses or allergies and worsening











ACQ total score 1.3
Data presented as mean (SD) or percentage.
BMI= body mass index, ICS= inhaled corticosteroids, FEV1= Forced expiratory flow in
of the FVC, ACQ= Asthma Control Questionnaire.psychological stress, and physical fatigue. After 10 in-depth
interviews, saturation of topics was attained.
Subsequently, 6 patients with and 5 patients without
SAD were identified to attend the focus group interviews.
Patients were selected based on a combination of spirom-
etry and IOS measures (Figure 1). Presence of SAD was
defined as both FEF50%< LLN and R5-R20 > 0.10 kPa/L/s.
Absence of SAD was defined as both FEF50% > LLN and
R5-R20 ≤ 0.10 kPa/L/s. The cut-off value for R5-R20 was
based on a study population of 110 healthy, never or cur-
rently smoking subjects, age 18–73 years (NCT00848406;
[19]). Of these subjects, 90% had an R5-R20< 0.10 kPa/L/s.
Methods of interviews and focus groups
All useful topics (items) were selected to be further dis-
cussed during the focus group interviews. Discussions in
the focus groups were literally and fully transcribed by
two authors of this article (LSG and EvdW). Qualitative
data management software (NVivo 9 [20]) was used. All
items mentioned in the in-depth and focus group inter-
views were organized in groups of items of interest. Then,
a list of all items that differed between SAD and non-SAD
patients of the focus groups was created. Afterwards, the
list was back- and forward translated by a native English
speaking pulmonology expert and two Dutch bilingual pri-
mary care researchers with knowledge of pulmonology.
The study and procedures were approved by the med-
ical ethics committee of the University Medical Center
Groningen and all patients gave written informed consent.
Results
The clinical characteristics of the 7 asthma patients with
SAD and 3 patients without SAD participating in the in-
dividual in-depth interviews are presented in Table 2. Both
groups of patients were comparable for most clinical
parameters, except FEV1/FVC ratio and residual volume












one second, FVC= forced vital capacity, FEF50%= forced expiratory flow at 50%
Table 2 Patient characteristics participating in the focus groups
In-depth interview group Focus group
With SAD (n= 7) Without SAD (n= 3) With SAD (n= 6) Without SAD (n= 5)
median (range) median (range) p-value median (range) median (range) p-value
Age (years) 45 (25–73) 52 (20–63) 0.833 54 (25–73) 47 (36–51) 0.247
Gender (female/male) 5/2 2/1 1.000 5/1 4/1 1.000
BMI (kg/m2) 28 (23–39) 36 (32–38) 0.117 29 (23–52) 32 (24–38) 0.792
Smoking (current/ex/never%) 1/4/2 1/1/1 0.728 0/5/1 0/1/4 0.080
ICS (yes/no) 5/2 3/0 1.000 4/2 3/2 0.497
FEV1 (%predicted) 79 (66–104) 99 (94–123) 0.117 81 (76–88) 112 (97–127) 0.004
FEV1/FVC (%) 62 (52–73) 83 (81–89) 0.017 64 (52–77) 83 (80–88) 0.004
FEF50% (%predicted) 37 (23–62) 107 (89–115) NA 40 (23–55) 114 (82–122) NA
RV (%predicted) 120 (88–160) 72 (71–89) 0.033 120 (88–160) 88 (77–98) 0.017
IOS R20 (kPa/l/s) 0.39 (0.29-0.50) 0.33 (0.32-0.40) 0.517 0.39 (0.34-0.67) 0.38 (0.26-0.49) 0.429
IOS R5-R20 (kPa/l/s) 0.27 (0.10-0.44) 0.19 (0.11-0.25) 0.383 0.25 (0.14-0.29) 0.05 (0.01-0.08) NA
IOS X5 (kPa/l/s) −0.22 (−0.49;-0.12) −0.23 (−0.26;-0.11) 1.000 −0.23 (−0.49;-0.22) −0.07 (−0.12;-0.06) 0.004
PC20 methacholine
# (mg/ml) 1.1 (0.1-6.4) 3.5 (1.3-23.9) 0.183 1.13 (0.14-5.55) 9.8 (2.8-20.9@) 0.017
ACQ (total score) 0.5 (0.0-1.5) 2.0 (0.0-2.2) 0.383 0.6 (0.0-1.3) 1.0 (0.3-2.2) 0.177
BHQ symptoms (score) 0.4 (0.0-2.5) 1.8 (0.3-3.1) 0.383 1.3 (0.0-2.7) 1.9 (1.3-2.7) 0.329
BHQ stimuli (score) 1.2 (0.0-4.3) 1.8 (0.0-4.3) 0.833 2.5 (0.1-3.8) 2.5 (0.9-4.1) 0.662
@Patient with a PC20 20.9 mg/ml methacholine used 800 μg ICS.
#Values were log transformed. Differences were tested with a non-parametric test. For ordinal
variables differences were tested with the Fisher’s Exact test or Chi-square test as appropriate.
BMI= body mass index, ICS= inhaled corticosteroids, FEV1= Forced expiratory flow in one second, FVC= forced vital capacity, FEF50%= forced expiratory flow at 50%
of the FVC, RV= residual volume, IOS= impulse oscillometry, R20: Resistance of the respiratory system at 20 Hertz, R5-R20: Difference between the resistance at 5Hz
and 20Hz, X5= Reactance of the respiratory system at 5 Hertz, PC20= provocative concentration causing a 20% fall in FEV1, ACQ= Asthma Control Questionnaire,
BHQ= Bronchial Hyperresponsiveness Questionnaire.
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ferences between the group with and without SAD were
observed in most parameters, except for lung function
parameters. Four patients of the SAD focus group had
also participated in the individual in-depth interviews.
Patients participating in the in-depth interview or focus
group did not use small particle inhalation medication.
Item organization and selection
All items that appeared to be different between the two
groups were selected and a total of 63 items was retained.
All items were phrased in a positive way (for example “I
have an immediate reaction to cats”). Of these phrases, 21
phrases were in line with symptoms of patients with SAD
and not of patients without SAD (e.g. “When I feel asth-
matic, I feel it in my chest.”), whereas 41 phrases were
in line with symptoms of patients without SAD (e.g. “I
frequently have a hoarse or husky voice”). In addition
one open question (“At what age did you first suffer from
asthma symptoms?”) was added. The resulting 63 items
are shown in Table 3 and are divided in the following 10
domains.
1. The Asthma Symptoms domain (13 items); patients
with SAD reported to wheeze more often and moreeasily. All patients with SAD were unable to breathe
in deeply when having asthma symptoms, while this
was not reported by any of the patients without SAD.
2. The Ears, Nose and Throat domain (10 items); these
symptoms were only mentioned by patients without
SAD.
3. The Localization of Symptoms domain (6 items)
includes items concerning the exact spot of pain and
other signs when feeling asthmatic. SAD patients for
example mentioned an oppressive feeling and pain in
the chest, whereas patients without SAD felt bloated
and sometimes had pain in the middle or the upper
part of the back.
4. The BHR to Exercise domain (8 items); patients with
SAD mentioned problems with regular physical
activities, while those without SAD were rarely
hindered in their activities.
5. The BHR to Allergens domain (4 items) shows that
patients with SAD react to birds and cats, while
those without SAD cannot stand wool or down.
6. The BHR to Weather Changes domain (6 items)
reflects that both groups seem to react to weather
changes, but in a different way.
7. The Stress and Fatigue domain (7 items); patients
with SAD reported more asthma symptoms in
Table 3 63-items of the SADT
Without SAD With SAD
Domain 1: Asthma symptoms Concentrating on my breathing helps me when
I feel asthmatic.
I’m not able to breathe in deeply
when I feel asthmatic.
People often tell me they can hear me breathing,
even in a calm situation.
I sometimes wheeze when I’m at
ease or in rest.
I only wheeze when I feel very asthmatic. When I’m physically active (like walking
the stairs), I sometimes wheeze.
I often cough unexpectedly. I can feel suddenly asthmatic without
having any other symptoms.
I often cough superficially (tickling cough) before
I get bothered by coughing more deeply.
I can see it coming when I get my asthma. I almost always feel slightly asthmatic and
I take a rescue puff regularly.
I often have a period without feeling asthmatic and
without needing rescue puffs.
I have suffered from bronchitis.
Domain 2: Ear/nose/ throat
complaints
My asthma symptoms are preceded by the flu or a cold. I usually have runny or painful eyes when
I have hay fever.
When I feel asthmatic, I almost always have symptoms
comparable to a cold.
I usually get a cold first, and thereafter start coughing.
I often suffer with my ears.
I often have runny or painful eyes without having hay fever.
I frequently have a hoarse or husky voice.
When I feel asthmatic, it often comes with symptoms of
my throat, nose, ears or eyes.
When I feel asthmatic, I often, also suffer from a sore throat.
My tonsils or adenoids have been removed.
Domain 3: Localization of symptoms When I feel asthmatic, I feel it in the middle of my back. When I feel asthmatic, I have a pressing
and oppressive feeling.
When I feel asthmatic, I feel it in the top of my back. When I feel asthmatic, I feel it in my chest.
When I feel asthmatic, I feel a stab or a sting in my
back or my ribs.
When I feel asthmatic, I sometimes feel bloated.
Domain 4: BHR to exercise As a child, I always participated in all games and sports. Actually, I cannot perform strenuous exercise
or sport, because I will become asthmatic.
I am able to walk a long distance without resting. Physical activities always make my asthma worse.
When I’m not ill, I can easily do physical activities such
as walking the stairs.
When I feel asthmatic when exercising, it is very often
due to the environment (grass, trees, flowers…).
When I feel asthmatic when exercising, it is very often
due to the weather.
Sometimes I go running or jogging.
Domain 5: BHR to allergens I cannot stand woolen blankets or clothes. I have an immediate reaction to birds.
I cannot stand the down filling in pillows. I have an immediate reaction to cats.
Domain 6: BHR to weather changes I tire more rapidly due to weather changes. My asthma worsens in autumn.
My breathing becomes easier in cold air. I feel asthmatic more rapidly due to
weather changes.
I always sleep with an open window, otherwise I feel
asthmatic.
I feel asthmatic when I suddenly enter a
cold environment.
Domain 7: Stress and fatigue I rapidly get tired due to my asthma symptoms. In stressful situations, I get particularly
asthma symptoms.
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1Table 3 63-items of the SADT (Continued)
Feeling tired is as much part of my asthma as
feeling short of breath.
In stressful situations I have physical symptoms
such as complaints of the nose, throat or voice.
I tire more rapidly due to my asthma symptoms.When I’m feeling tired I will
probably get asthmatic in
a few days.
When I feel asthmatic, I often, also
have a headache.
Domain 8: Gastro-intestinal tract Sometimes I feel asthmatic or out of breath
because of heartburn.
Sometimes, when I’m short of breath, it can
be a relief to burp.
Sometimes I have stomach problems which
can make me feel asthmatic.
Domain 9: Skin I get eczema because of weather changes.
I get skin problems (like eczema) when touching
some kinds of food (e.g. fruit or vegetables).
My asthma symptoms and eczema alternate.
Domain 10: Miscellaneous I often get car sick or travel sick.
I have more than three close relatives suffering
from asthma or comparable illnesses.
At what age did you first suffer from asthma
symptoms?
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more asthma symptoms related to periods of fatigue.
8. The Gastrointestinal Complaints domain (3 items);
Patients without SAD mentioned to suffer
sometimes from gastrointestinal problems related to
their asthma, but asthma patients with SAD did not.
9. The Skin problems domain (3 items); only patients
with SAD reported eczema related to asthma.
0. The last domain (3 items) was named Miscellaneous.
Patients without SAD reported often getting car-sick
and having asthmatic relatives. Patients with SAD
reported to be somewhat older when their first
symptoms appeared. These items did not combine
with any other domains and were thus placed in this
last domain.Discussion
This is the first phase of the development of a question-
naire aiming to help identifying asthma patients with
SAD based on self-reported symptoms in clinical prac-
tice. Based on the differences that we found after ten in-
depth interviews and two focus groups in patients with
and without SAD, we identified a total of 63 items that
may help to differentiate between patients with and with-
out SAD. In short, we found that patients with SAD re-
ported to wheeze easily, were unable to breathe in deeply,
mentioned more symptoms related to BHR, experienced
more pronounced exercise-induced symptoms and morefrequently had allergic respiratory symptoms after expos-
ure to cats and birds.
Interestingly, a number of the observed differences be-
tween patients with and without SAD, are supported by
recent observations reported in the literature [21-31]. Our
finding that patients with SAD were unable to breathe
in deeply and reported to wheeze very easily may re-
flect hyperinflation, compatible with small airway clos-
ure. Mansur et al. also found a relationship between more
symptoms of wheezing and more severe small airways dys-
function during a methacholine provocation test [21]. In
addition, patients with SAD indicated that they had suf-
fered from bronchitis at least once in their life, whereas
patients without SAD did not. More frequent symptoms
and need of rescue treatment are compatible with worse
asthma control and the occurrence of asthma exacerba-
tions, findings that have been related to SAD in asthma in
previous studies as well [22-24].
Patients with SAD also reported more frequently symp-
toms of BHR to exercise, allergens and weather changes
(domains 4, 5 and 6). This is compatible with earlier stud-
ies on BHR showing that hyperresponsiveness is associated
with small airways obstruction in asthma [25-27]. Inter-
estingly, Zeidler et al. showed that patients with allergic
asthma exposed to cat allergens have predominantly a
response of the small airways measured by HRCT scan
[28]. Our asthma patients with SAD reported an immedi-
ate and strong response to cats. Indeed, these allergens
can be found on rather small particles (diameter<2.5 μm),
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patients without SAD [29]. In contrast, patients without
SAD reported to respond strongly to wool and down. This
might be related to house dust-mite excretion in these
tissues, which is found on larger particles (10 μm) [30].
Exercise induced symptoms were predominantly men-
tioned by patients with SAD, which is in line with a study
of Lee et al. showing an association between the severity of
exercise-induced response and an increased resistance of
the small airways [31].
For some of the observed differences between patients
with and without SAD we have not found corresponding
findings in the existing literature. These novel findings
might be interesting to study in a more systematic way in
further research regarding symptoms of SAD in asthma.
Our patients represent the asthma population as present
in the original primary care database of the asthma COPD
service from “Certe Laboratory”. Included patients had a
median age of 51 years and a median BMI of 30 kg/m2,
77% of the patients being female, whereas the asthma-
population of the primary care database had a mean age
of 53 with a mean BMI of 29 kg/m2 and consisted of 68%
females. The smoking habits of our study population, i.e.
12/47/41% current/never/ex smokers, were comparable
with the asthma-population of the primary care database.
Thus the final list of 63 items is not limited to non-
smokers. This is of importance since a few studies have
suggested an important effect of smoking on SAD [32,33].
With exclusion of smokers we could have missed signs
and symptoms important for SAD.
The study has some limitations. The scientific commu-
nity has so far not provided an agreed gold standard for
the diagnosis of SAD in asthma. We did not use Computed
Tomography (CT scan) or multiple breath nitrogen wash-
out tests to assess the presence of small airways disease,
yet we used a very precise way of selecting and reselecting
patients with and without SAD, based on a combination of
both FEF50% and R5-R20 values. These parameters are fre-
quently described as a reliable way to assess SAD [8,10].
The division in patients below and above the LLN of the
FEF50% has also been used in a previous study to compare
patients with and without SAD [26]. For the R5-R20 we
used a cutoff value that was based on a group of 110 well
selected and well characterized healthy controls [19].
In summary, the present study is a first step in the de-
velopment of the SADT. We generated 63 items for the
new small airways dysfunction tool, the SADT, which
aims to identify patients with SAD. The items that were
identified cover a broad area of asthma symptoms related
to airway hyperresponsiveness, response to allergens and
physical exercise. All generated items will be further tested
and validated in a large asthma population with a wide
spectrum of severity during a multinational longitudinal
study that will start in the near future. The next study willretain the most relevant items with which a short and
simple tool to determine SAD in asthma patients will be
realized.
Clinical implications
Identification of SAD in asthma patients may be possible
using this simple and non-invasive tool. Differences in
symptoms and signs between asthma patients with and
without SAD were identified.
Capsule summary
Based on differences in symptoms and signs, habits and
health related issues between asthma patients with and
without SAD, 63 items were combined to be entered in
the next phase of the SADT.
Additional file
Additional file 1: Measurement specifications.
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